PLENAXIS Drug Patent Profile
✉ Email this page to a colleague
When do Plenaxis patents expire, and what generic alternatives are available?
Plenaxis is a drug marketed by Speciality European and is included in one NDA.
The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.
Summary for PLENAXIS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 3 |
Patent Applications: | 5,098 |
DailyMed Link: | PLENAXIS at DailyMed |
Recent Clinical Trials for PLENAXIS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
PRAECIS Pharmaceuticals Inc. | Phase 4 |
PRAECIS Pharmaceuticals Inc. | Phase 2 |
Speciality European Pharma Limited | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for PLENAXIS
US Patents and Regulatory Information for PLENAXIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PLENAXIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PLENAXIS
See the table below for patents covering PLENAXIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2007302695 | LHRH ANTAGONIST PEPTIDE | ⤷ Try a Trial |
Austria | 378059 | ⤷ Try a Trial | |
South Korea | 20000069432 | ⤷ Try a Trial | |
Denmark | 1188768 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PLENAXIS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0794961 | 91857 | Luxembourg | ⤷ Try a Trial | 91857, EXPIRES: 20200922 |
0794961 | CR 2011 00004 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922 |
0794961 | C300484 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922 |
0794961 | 11C0015 | France | ⤷ Try a Trial | PRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |